Clear-cell metastatic renal cell carcinoma
Information
- Disease name
- Clear-cell metastatic renal cell carcinoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02978404 | Active, not recruiting | Phase 2 | Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases | June 2, 2017 | December 31, 2023 |
| NCT01521715 | Completed | Phase 4 | First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma | January 24, 2012 | July 31, 2017 |
| NCT01693822 | Completed | Phase 2 | A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy | October 2012 | February 28, 2022 |
| NCT01715935 | Completed | Phase 2 | Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus | June 2012 | April 2016 |
| NCT02228954 | Completed | IMaging PAtients for Cancer Drug selecTion - Renal Cell Carcinoma (IMPACT-RCC) | December 2014 | October 19, 2021 | |
| NCT01472081 | Completed | Phase 1 | Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) | February 9, 2012 | June 3, 2021 |
| NCT05745142 | Completed | A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine. | February 23, 2023 | February 23, 2023 | |
| NCT02724020 | Completed | Phase 2 | MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma | June 30, 2016 | October 13, 2020 |
| NCT02917772 | Completed | Phase 2 | Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma | October 2016 | October 2022 |
| NCT06279403 | Not yet recruiting | Phase 2 | Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma | March 1, 2024 | March 1, 2029 |
| NCT05263050 | Recruiting | Phase 2 | Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma | January 21, 2022 | February 2027 |
| NCT05567588 | Recruiting | Phase 2 | Pembrolizumab Plus Radiotherapy for Advanced Renal Cancer | October 31, 2022 | October 31, 2025 |
| NCT02543645 | Terminated | Phase 1 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | October 2015 | May 22, 2017 |
| NCT02386111 | Terminated | Phase 1 | A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma | May 2015 | November 3, 2017 |
| NCT02535351 | Terminated | Phase 3 | Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery | November 2015 | September 28, 2018 |
| NCT02570789 | Terminated | Phase 4 | Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy | December 2012 | March 1, 2021 |
| NCT02880943 | Unknown status | Phase 1/Phase 2 | Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL) | October 2016 | February 2021 |